Background: Two atopic patients suffering from severe allergy difficult to handle by conventional medication were given Xolair despite an IgE level <30 kU/l. Methods: Increasing dosages were given and monitored by clinical evaluation and CD-sens to clinically relevant allergens. The patients’ IgE antibody fractions were 11–14%. Results: Xolair dosages extrapolated from a recommended dose for IgE of 30–75 kU/l were adapted to the patients’ IgE body pool but had very little effect. The double dose resulted in some clinical improvement and a decrease in CD-sens. However, not until the dose was doubled again did the patients become symptom free, although 1 patient needed some additional drugs but no oral steroids. CD-sens turned negative to 5 of the 7 tested allergens. Conclusions: Xolair is most useful also in atopics with an IgE level <30 kU/l. The dose must be adjusted to the size of the IgE antibody fraction adding all non-cross-reacting, clinically relevant specificities.

Keywords:
CD-sens, Low IgE level, Basophil, IgE antibody
1.
Xolair (omalizumab), summary of product characteristics. http://www.emea.eu.int/humandocs/PDFs/EPAR/Xolair/H-606-PI-en-pdf.
2.
Johansson SGO, Nopp A, Öman H, Ankerst J, Cardell LO, Grönneberg R, et al: The size of the disease relevant IgE antibody fraction in relation to ‘total-IgE’ predicts the efficacy of anti-IgE (Xolair®) treatment. Allergy 2009;64:1472–1477.
3.
Johansson SGO, Öman H, Nopp A, Pettersson S: The importance of IgE antibody levels in anti-IgE treatment. Allergy 2006;61:1216–1219.
4.
Nopp A, Johansson SGO, Ankerst J, Bylin G, Cardell LO, Grönneberg R, et al: Basophil allergen threshold sensitivity. A useful approach to anti-IgE treatment efficacy evaluation. Allergy 2006;61:298–302.
5.
Johansson SGO, Nopp A, van Hage M, Olofsson N, Lundahl J, Wehlin L, et al: Passive IgE-sensitization by blood transfusion. Allergy 2005;60:1192–1199.
6.
Kaplan AP, Greaves M: Pathogenesis of chronic urticaria. Clin Exp Allergy 2009;39:777–787.
7.
Sears MR, Burrows B, Flannery EM, Herbison GP, Hewitt CJ, Holdaway MD: Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N Engl J Med 1991;325:1067–1071.
8.
Bousquet J, Rabe K, Humbert M, Chung KF, Berger W, Fox H, Ayre G, Chen H, Thomas K, Blogg M, Holgate S: Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 2007;101:1483–1492.
9.
Nopp A, Johansson SGO, Lundberg M, Öman H: Simultaneous exposure of several allergens has an additive effect on multisensitized basophils. Allergy 2006;61:1366–1368.
10.
Nopp A, Johansson SGO, Ankerst J, Palmqvist M, Öman H: CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment. Allergy 2007;62:1175–1181.
11.
Nopp A, Cardell LO, Johansson SGO, Öman H: CD-sens: a biological measure of immunological changes stimulated by ASIT. Allergy 2009;64:811–814.
12.
Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG, Mokhtarani M, Seyfert-Margolis V, Asare A, Bateman K, Deniz Y: Omalizumab pre-treatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006;117:134–140.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.